|
1.
|
|
11 p, 1.6 MB |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
/
Eron, J. J. (University of North Carolina School of Medicine) ;
Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ;
Cunningham, D. (Pueblo Family Physicians) ;
Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Post, F. (King's College Hospital NHS Foundation Trust) ;
De Wit, Stéphane (Université Libre de Bruxelles) ;
Lathouwers, E. (Janssen Pharmaceutica NV) ;
Hufkens, V. (Janssen Pharmaceutica NV) ;
Jezorwski, J. (Janssen Research & Development) ;
Petrovic, R. (Janssen Pharmaceutica NV) ;
Brown, K. (Janssen Pharmaceutica NV) ;
Van Landuyt, E. (Janssen Pharmaceutica NV) ;
Opsomer, M. (Janssen Pharmaceutica NV) ;
De Wit, Stéphane (Université Libre de Bruxelles) ;
Florence, E. (Institute of Tropical Medicine) ;
Moutschen, M. (Liège University Hospital (Bèlgica)) ;
Van Wijngaerden, E. (University Hospitals Leuven (Bèlgica)) ;
Vandekerckhove, Linos (Ghent University Hospital. (Bèlgica)) ;
Vandercam, B. (AIDS Reference center. Cliniques Universitaires Saint-Luc) ;
Brunetta, J. (Maple Leaf Medical Clinic) ;
Conway, B. (Vancouver Infectious Diseases Center) ;
Klein, M. (Division of Infectious Diseases. Faculty of Medicine. McGill University Health Centre) ;
Murphy, D. (Institut national de santé publique du Québec) ;
Rachlis, A. (Sunnybrook Health Sciences Centre) ;
Shafran, S. (Department of Medicine. University of Alberta) ;
Walmsley, S. (University Health Network) ;
Ajana, F. (Infectious Diseases Department. Tourcoing Hospital) ;
Cotte, L. (Hospices Civils de Lyon. Hôpital de la Croix-Rousse) ;
Girardy, P. M. (University Pierre & Marie Curie) ;
Katlama, C. (HIV Clinical Research Unit) ;
Molina, J. M. (Department of Infectious Diseases. St-Louis Hospital APHP. University of Paris Diderot) ;
Poizot-Martin, I. (Clinical Immuno-Hematology Department. Aix-Marseille University. Sainte-Marguerite University Hospital and Inserm U912) ;
Raffi, F. (CHU Hôtel Dieu) ;
Rey, D. (Le Trait d'Union. HIV-Infection Care Center. Hôpitaux Universitaires de Strasbourg) ;
Reynes, J. (University Hospital of Montpellier (França)) ;
Teicher, E. (Infectious Diseases Department. APHP. Hôpital Bicêtre) ;
Yazdanpanah, Y. ;
Gasiorowski, J. (Independent Laboratory for Monitoring Infections among Drug Users at the Department of Infectious Diseases. Liver Disease and Acquired Immune Deficiencies. Wroclaw Medical University) ;
Halota, W. (Department of Infectious Diseases and Hepatology. Nicolaus Copernicus University) ;
Horban, A. (Medical University of Warsaw. Department for Adult's Infectious Diseases) ;
Piekarska, A. (Department of Infectious Diseases and Hepatology. Medical University of Lodz) ;
Witor, A. (Regional Hospital. Out-Patient's Clinic for Immune Deficiency) ;
Arribas, Jose (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Perez-Valero, I. (Hospital Universitario La Paz (Madrid)) ;
Berenguer, Juan (Hospital General Universitario Gregorio Marañón) ;
Casado, José A. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Gatell, J. M. (Infectious Diseases Department. HCB) ;
Gutiérrez, Félix (Hospital General Universitario de Elche) ;
Galindo, María José (Hospital Clínic Universitari (València)) ;
Gutiérrez Macià, Mª Del Mar (Institut d'Investigació Biomèdica Sant Pau) ;
Iribarren, J. A. (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Knobel Freud, Hernando (Hospital del Mar (Barcelona, Catalunya)) ;
Negredo Puigmal, Eugènia. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Pineda, J. A. (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ;
Podzamczer, Daniel (Institut d'Investigació Biomèdica de Bellvitge) ;
Sogorb, J. P. (Hospital Universitario 12 de Octubre (Madrid)) ;
Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Ricart, C. (Department of Microbiology. School of Medicine. University of Valencia) ;
Rivero Román, Antonio (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Santos Gil, I. (Hospital Universitario de la Princesa (Madrid)) ;
Blaxhult, A. (Department of Infectious Diseases. Venhälsan. Södersjukhuset) ;
Flamholc, L. (Skåne University Hospital (Suècia)) ;
Gisslèn, M. (Department of Infectious Diseases. University of Gothenburg) ;
Thalme, A. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Fehr, J. (University Hospital Zurich (Suïssa)) ;
Rauch, A. (Bern University Hospital) ;
Stoeckle, M. (University Hospital Basel (Basilea, Suïssa)) ;
Clarke, A. (Claude Nicol Centre. Royal Sussex County Hospital. Brighton and Sussex University Hospitals NHS Trust) ;
Gazzard, B. G. (St. Stephen's Centre. Department of HIV/Genito-Urinary Medicine. Chelsea and Westminster Hospital) ;
Johnson, M. A. (Queen Mary University) ;
Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ;
Post, F. (King's College Hospital NHS Foundation Trust) ;
Ustianowski, Andrew (Regional Infectious Diseases Unit. North Manchester General Hospital) ;
Waters, L. (University College London Hospital) ;
Bailey, J. (Department of Medicine. Johns Hopkins University School of Medicine) ;
Benson, P. (Be Well Medical) ;
Bhatti, L. (AIDS Healthcare Foundation) ;
Brar, I. (Henry Ford Hospital) ;
Bredeek, U. F. (Metropolis Medical PC) ;
Brinson, C. (Central Texas Clinical Research) ;
Crofoot, G. (The Crofoot Research Center) ;
Cunningham, D. (Pueblo Family Physicians) ;
DeJesus, E. (Pueblo Family Physicians) ;
Dietz, C. (Orlando Immunology Center) ;
Dretler, R. (HIV Medicine. Kansas City Free Health Clinic) ;
Eron, J. (Infectious Disease Specialists of Atlanta) ;
Felizarta, F. (Private Practice) ;
Fichtenbaum, C. (University of Cincinnati College of Medicine) ;
Gallant, J. (Southwest CARE Center) ;
Gathe, J. (Therapeutic Concepts) ;
Hagins, D. (Georgia Department of Public Health. Chatham Care Center) ;
Henn, S. (Whitman-Walker Health) ;
Henry, W. K. (Department of Medicine. University of Minnesota Washington University School of Medicine) ;
Huhn, G. (Ruth M. Rothstein CORE Center) ;
Jain, M. (Department of Internal Medicine. University of Texas Southwestern Medical Center) ;
Lucasti, C. (South Jersey Infectious Disease) ;
Martorell, C. (Infectious Disease and The Research Institute) ;
McDonald, C. (Tarrant County Infectious Disease Associates) ;
Mills, A. (Southern California Men's Medical Group) ;
Morales-Ramirez, J. (Clinical Research Puerto Rico Inc.) ;
Mounzer, K. (Philadelphia FIGHT) ;
Nahass, R. (ID Care) ;
Olivet, H. (Community Research Initiative of New England) ;
Osiyemi, O. (Triple O Research Institute PA) ;
Prelutsky, D. (Department of Internal Medicine. Washington University School of Medicine) ;
Ramgopal, M. (Midway Immunology Center. Fort Pierce) ;
Rashbaum, B. (Capital Medical Associates) ;
Richmond, G. (Broward General Medical Center) ;
Ruane, P. (Ruane Clinical Research Group) ;
Scarsella, A. (Pacific Oaks Medical Group) ;
Scribner, A. (DCOL Center for Clinical Research) ;
Shalit, P. (Peter Shalit MD and Associates) ;
Shamblaw, D. (La Playa Medical Group) ;
Slim, J. (Department of Infectious Diseases. Seton Hall University) ;
Tashima, K. (The Miriam Hospital. Warren Alpert Medical School of Brown University) ;
Voskuhl, G. (AIDS Arms. Inc.) ;
Ward, D. (Dupont Circle Physicians Group) ;
Wilkin, A. (Wake Forest School of Medicine) ;
de Vente, J. (Living Hope Foundation) ;
Universitat Autònoma de Barcelona
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. [...]
2019 -  10.1016/j.antiviral.2019.104543
Antiviral Research, Vol. 170 (october 2019) , p. 104543
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
